- Home
- INMB
as 01-21-2025 4:00pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 103.1M | IPO Year: | 2019 |
| Target Price: | $21.00 | AVG Volume (30 days): | 369.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $14.74 | Next Earning Date: | 10-31-2024 |
| Revenue: | $42,000 | Revenue Growth: | -81.25% |
| Revenue Growth (this year): | -93.16% | Revenue Growth (next year): | N/A |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
TipRanks
10 days ago
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
a month ago
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
Exec Edge
2 months ago
OmniScience and INmune Bio Partner for Alzheimer’s Trial
MT Newswires
2 months ago
INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial
Business Wire
2 months ago
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
GlobeNewswire
2 months ago
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Simply Wall St.
3 months ago
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)
GuruFocus.com
3 months ago
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.